Information and frequently asked questions regarding the MammaPrint®(70 gene signature) test for early breast cancer
16 April, 2019

The purpose of this document is to provide information for patients and health professionals about the Medical Services Advisory Committee (MSAC) conclusion in relation to public funding of the MammaPrint® (70 gene signature) test. Information is presented in the form of frequentlyasked questions to support discussions regarding the test and the MSAC outcome.

Go Back

Page last updated:

Copyright © 2020 RCPA. All rights reserved.